Deutsche Bank Maintains Hold on Boston Scientific

Deutsche Bank is out with its report today on Boston Scientific BSX, maintaining Hold. In a note to clients, Deutsche Bank writes, "Medtronic's results did not change our view on BSX shares. MDT's results underscore the ICD market is challenged (more than expected) and when combined with our outlook for the stent/IC markets, we continue to believe BSX shares have a long road to a recovery. The recent announcement of CEO Elliott's year-end retirement adds uncertainty." At the time of posting, shares of BSX were trading pre-market at $6.89, up 3.30% from Tuesday's close.